- Home
- STTK vs LANV Comparison
STTK vs LANV Comparison
Compare STTK & LANV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- LANV
- Stock Information
- Founded
- STTK 2016
- LANV 2015
- Country
- STTK United States
- LANV China
- Employees
- STTK N/A
- LANV N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- LANV Blank Checks
- Sector
- STTK Health Care
- LANV Finance
- Exchange
- STTK Nasdaq
- LANV Nasdaq
- Market Cap
- STTK 37.6M
- LANV 258.1M
- IPO Year
- STTK 2020
- LANV N/A
- Fundamental
- Price
- STTK $0.82
- LANV $2.20
- Analyst Decision
- STTK Hold
- LANV
- Analyst Count
- STTK 4
- LANV 0
- Target Price
- STTK $3.00
- LANV N/A
- AVG Volume (30 Days)
- STTK 396.2K
- LANV 39.1K
- Earning Date
- STTK 07-31-2025
- LANV 08-25-2025
- Dividend Yield
- STTK N/A
- LANV N/A
- EPS Growth
- STTK N/A
- LANV N/A
- EPS
- STTK N/A
- LANV N/A
- Revenue
- STTK $4,606,000.00
- LANV $340,211,202.00
- Revenue This Year
- STTK N/A
- LANV $11.74
- Revenue Next Year
- STTK N/A
- LANV $11.11
- P/E Ratio
- STTK N/A
- LANV N/A
- Revenue Growth
- STTK 69.65
- LANV N/A
- 52 Week Low
- STTK $0.69
- LANV $0.91
- 52 Week High
- STTK $4.99
- LANV $2.69
- Technical
- Relative Strength Index (RSI)
- STTK 37.21
- LANV 53.77
- Support Level
- STTK $0.77
- LANV $2.00
- Resistance Level
- STTK $1.14
- LANV $2.51
- Average True Range (ATR)
- STTK 0.09
- LANV 0.14
- MACD
- STTK -0.03
- LANV 0.01
- Stochastic Oscillator
- STTK 9.88
- LANV 39.22
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About LANV Lanvin Group Holdings Limited
Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the Wolford segment.